Evidence map›Paper›PMID 38024242›Full record

ArticleNeuro-oncology advances

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma.

Iris Divé, Katharina J Weber, Tabea I Hartung, Eike Steidl, Marlies Wagner, Elke Hattingen, Kea Franz, Emmanouil Fokas, Michael W Ronellenfitsch, Ulrich Herrlinger and 2 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Iris DivéDr. Senckenberg Institute of Neurooncology, Goethe University, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0003-1096-5626
Katharina J WeberUniversity Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
Tabea I HartungInstitute of Neurology (Edinger-Institute), Goethe University, Frankfurt am Main, Germany.
Eike SteidlUniversity Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
Marlies WagnerInstitute of Neuroradiology, Goethe University, Frankfurt am Main, Germany.
Elke HattingenUniversity Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
Kea FranzDr. Senckenberg Institute of Neurooncology, Goethe University, Frankfurt am Main, Germany.
Emmanouil FokasFrankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.
Michael W RonellenfitschDr. Senckenberg Institute of Neurooncology, Goethe University, Frankfurt am Main, Germany.
Ulrich HerrlingerDepartment of Neurology, University Medical Center Bonn, Germany.
Patrick N HarterUniversity Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
Joachim P SteinbachDr. Senckenberg Institute of Neurooncology, Goethe University, Frankfurt am Main, Germany.
Goethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth. Methods: From our methylome database of IDH (isocitrate dehydrogenase)-wildtype GB, we identified 158 non-GC and 65 GC cases. GC cases were subdivided into diffuse-infiltrative (subtype 1), multifocal (subtype 2), or tumors with 1 solid mass (subtype 3). We compared clinical, histological, and molecular parameters and conducted a reference-free tumor deconvolution of DNA methylation data based on latent methylation components (LMC). Results: GC subtype 1 less frequently showed contrast-enhancing tumors, and more frequently lacked morphological GB criteria despite displaying GB DNA methylation profile. However, the tumor deconvolution did not deliver a specific LMC cluster for either of the GC subtypes. Employing the reference-based analysis MethylCIBERSORT, we did not identify significant differences in tumor cell composition. The majority of both GC and non-GC patients received radiochemotherapy as first-line treatment, but there was a major imbalance for resection. The entire GC cohort had significantly shorter overall survival (OS) and time to treatment failure (TTF) than the non-GC cohort. However, when filtering for cases in which only stereotactic biopsy was performed, the comparison of OS and TTF lost statistical significance. Conclusions: Our study offers clinically relevant information by demonstrating a similar outcome for GB with GC growth pattern in the surgically matched analysis. The limited number of cases in the GC subgroups encourages the validation of our DNA methylation analysis in larger cohorts.

Indexed as

glioblastomagliomatosis cerebrioverall survivaltreatment

Identifiers

PMID38024242
PMCPMC10676054
OpenAlexW4387702894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.